Last Updated: November 16, 2026

Details for Patent: 10,945,987

« Back to Dashboard


Which drugs does patent 10,945,987 protect, and when does it expire?

Patent 10,945,987 protects EPSOLAY and is included in one NDA.

This patent has twelve patent family members in two countries.

Summary for Patent: 10,945,987
Title:Method for providing early onset of action in the treatment of rosacea
Abstract:A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.
Inventor(s):Ofer Toledano, Ofra Levy-Hacham, Ori NOV, Vered RAM
Assignee: Mayne Pharma LLC
Application Number:US16/794,734
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;
Patent landscape, scope, and claims:

US Patent 10,945,987: Scope, Claim Analysis, Epsolay Coverage and Rosacea Patent Landscape

US Patent 10,945,987 protects specific once-daily regimens using a topical, encapsulated or microencapsulated benzoyl peroxide formulation for rosacea. The patent does not broadly cover all benzoyl peroxide products or all rosacea treatments. Its practical target is a 2.5% to 10% benzoyl peroxide cream or emulsion, particularly the 5% microencapsulated formulation marketed as Epsolay.

The claims are method-of-treatment claims built around clinical-response thresholds, early onset of action, lesion-count reductions and formulation characteristics. The patent’s nominal expiration date is July 30, 2035, subject to any applicable patent-term adjustment or extension recorded by the USPTO or FDA.

What drug and formulation does US Patent 10,945,987 protect?

The patent protects treatment of rosacea with a topical pharmaceutical composition having all or substantially all of the following limitations:

Limitation Requirement in the independent claims
Active ingredient Benzoyl peroxide
Concentration About 2.5% to about 10% w/w
Preferred concentration About 5% w/w
Other active ingredients Benzoyl peroxide must be the only active ingredient
Dosage form Cream or emulsion
Delivery technology Encapsulated and/or microencapsulated benzoyl peroxide
Dosing Topical application once daily
Treatment duration At least about 2, 4, 8 or 12 weeks, depending on claim construction
Disease Rosacea
Clinical endpoint IGA improvement, clear or almost clear status, inflammatory-lesion reduction or a specified early-response pattern
Treatment context Benzoyl peroxide is the sole active ingredient administered during the regimen

The independent claims are claims 1, 9 and 17. Claims 2-8 depend from claim 1, claims 10-16 depend from claim 9, and claims 18-24 depend from claim 17.

The patent is therefore narrower than a composition patent covering benzoyl peroxide itself. A conventional 5% benzoyl peroxide gel used for acne would not necessarily infringe because it may lack the rosacea indication, cream or emulsion dosage form, encapsulation, once-daily regimen or clinical-response limitations.

What are the three independent claims in US 10,945,987?

Claim 1: IGA-based early response

Claim 1 covers a once-daily regimen in which a subject with rosacea receives a 2.5% to 10% benzoyl peroxide cream or emulsion, with benzoyl peroxide as the only active ingredient and in encapsulated or microencapsulated form.

The regimen must produce a primary success rate ranging from about 9% to about 40%, measured as:

  • A two-grade improvement in Investigator Global Assessment; and
  • A status of clear or almost clear.

The claim requires at least about 9% success after approximately two weeks. Dependent claims add higher response thresholds:

Claim Required primary-response result
1 At least about 9% after about 2 weeks
2 At least about 25% after about 4 weeks
3 At least about 40% after about 8 weeks

The claim also identifies first-line use, several rosacea subtypes, extended-release delivery and adverse-event performance comparable to or better than vehicle control as dependent limitations.

Claim 9: inflammatory-lesion reduction

Claim 9 uses the same core formulation and regimen but defines success through mean inflammatory-lesion count reduction from baseline.

Claim Required secondary-response result
9 At least about 40% after at least about 2 weeks
10 At least about 55% after at least about 4 weeks
11 At least about 65% after at least about 8 weeks

This claim set is commercially important because it tracks the principal clinical value of a papulopustular rosacea treatment: reduction in inflammatory lesions.

Claim 17: early absolute lesion-count reduction

Claim 17 covers the same core treatment but uses a different efficacy relationship. It requires that the absolute reduction in lesion count after approximately two weeks be at least twice the absolute reduction after approximately four weeks.

That limitation is unusual. On its face, it requires a larger absolute reduction during the earlier interval than during the later interval. A product sponsor defending or asserting the claim would need to establish how the comparison is calculated, including whether “after about two weeks” and “after about four weeks” refer to cumulative reduction from baseline or interval-specific reduction.

How broad is the patent’s protection?

The patent has meaningful commercial coverage but limited literal breadth.

Core protected product profile

The strongest infringement case exists where a product is:

  1. A prescription or physician-directed rosacea treatment;
  2. A cream or emulsion;
  3. Formulated with 5% benzoyl peroxide;
  4. Encapsulated or microencapsulated;
  5. Applied once daily; and
  6. Marketed with clinical claims involving rapid IGA improvement or inflammatory-lesion reduction.

That profile closely tracks Epsolay.

Products likely outside the literal claim scope

The following design choices may avoid one or more express claim limitations:

Design choice Potential effect
Benzoyl peroxide below 2.5% or above 10% Outside the stated concentration range
Non-encapsulated benzoyl peroxide Outside the encapsulation limitation
Gel, lotion or foam rather than cream or emulsion Potentially outside the dosage-form limitation
More than one active ingredient Outside the “only active ingredient” limitation
Twice-daily rather than once-daily administration Potentially outside the dosing limitation
Acne-only labeling May weaken method-of-use and induced-infringement theories
Treatment of non-rosacea inflammatory disease Outside the disease limitation
No clinical claims tied to the stated endpoints May complicate proof of the outcome limitations

These distinctions are not dispositive. A court would construe each limitation and assess literal infringement, equivalents, induced infringement and the actual instructions for use.

What formulation technology is protected?

The claims require that benzoyl peroxide be “encapsulated and/or microencapsulated.” The patent also identifies cream, emulsion and extended-release formulations.

The encapsulation limitation is commercially significant because benzoyl peroxide is chemically unstable and can cause irritation. Microencapsulation can separate benzoyl peroxide from the vehicle and skin until application, with the objective of improving stability, tolerability and delivery.

A formulation claim would normally focus on the composition or particle architecture. US 10,945,987 instead uses the formulation characteristic as part of a treatment-regimen claim. This creates two consequences:

  • The patent reaches use of a qualifying formulation in rosacea treatment.
  • It does not necessarily block independent development of a different encapsulation platform unless the resulting use satisfies the claim limitations.

A competing product could challenge whether its particles are “encapsulated” or “microencapsulated,” depending on the architecture and claim construction. The record would likely require particle characterization, manufacturing records and formulation-development data.

What is the FDA status of the product associated with this patent?

Epsolay is a prescription topical cream containing 5% benzoyl peroxide for inflammatory lesions of rosacea. The FDA approved Epsolay on April 25, 2022, under NDA 216152. Sol-Gel Technologies developed the product, and Galderma commercializes it in the United States. The FDA label identifies Epsolay as a once-daily topical treatment. (U.S. Food and Drug Administration, 2022)

Regulatory item Status
Product Epsolay
Active ingredient Benzoyl peroxide
Strength 5%
Dosage form Cream
Disease Inflammatory lesions of rosacea
Administration Topical, once daily
NDA 216152
Approval date April 25, 2022
Developer Sol-Gel Technologies
Commercial partner Galderma

The approved product aligns closely with the concentration, dosage form, once-daily administration and encapsulation limitations described in the patent.

What is the Orange Book status of US Patent 10,945,987?

US Patent 10,945,987 is associated with the Epsolay product and is listed among the patent rights relevant to the product’s FDA-approved use. The Orange Book is the primary FDA source for listed patents and exclusivity information for approved drug products. (U.S. Food and Drug Administration, 2024)

The patent’s nominal term runs to approximately July 30, 2035, based on the family priority date and the standard 20-year patent term framework. The operative expiration date should be read with any USPTO patent-term adjustment and any FDA-recorded patent-term extension.

The patent does not appear to be a biologic-exclusivity asset. Benzoyl peroxide is a small-molecule chemical active, and a competing applicant would generally pursue an ANDA or, depending on the proposed product and labeling, a 505(b)(2) application rather than a biosimilar application.

When does Epsolay lose exclusivity?

The relevant barriers are patent term, FDA regulatory exclusivity and any litigation or settlement restrictions.

Exclusivity barrier Practical assessment
US 10,945,987 Nominally expires around July 30, 2035, subject to PTA/PTE
New chemical entity exclusivity Unlikely because benzoyl peroxide is an established active ingredient
Three-year clinical-investigation exclusivity May apply only to qualifying new clinical investigations and approved conditions; it is not a substitute for the patent estate
Orphan-drug exclusivity Rosacea is not generally an orphan indication
Biosimilar exclusivity Not applicable
Generic approval pathway ANDA or potentially 505(b)(2), depending on product differences
Launch date Depends on patent challenges, settlement terms and court outcomes

A generic applicant may file a Paragraph IV certification alleging that a listed patent is invalid, unenforceable or not infringed. The patent does not automatically prevent an ANDA filing; it can delay approval and create litigation exposure.

Which companies are challenging the patent?

No publicly identified Paragraph IV challenger or final judgment affecting US Patent 10,945,987 is established by the materials supplied with the question. The commercial field remains centered on Sol-Gel and Galderma for the approved encapsulated 5% benzoyl peroxide rosacea product.

Potential challengers would include manufacturers with topical dermatology infrastructure and companies already selling benzoyl peroxide products. The strongest candidates would need to demonstrate pharmaceutical equivalence or establish a viable 505(b)(2) pathway while addressing the encapsulation, cream, rosacea-use and labeling limitations.

What patent litigation affects Epsolay?

The principal litigation risk is likely to arise from a future ANDA Paragraph IV filing rather than from biosimilar litigation. A generic applicant could contest the patent through several theories:

Claim construction

The terms “about,” “early onset of action,” “encapsulated,” “microencapsulated,” “cream,” “emulsion” and “sole active ingredient” may require judicial construction.

Enablement and written description

The patent claims a concentration range, multiple treatment periods, several rosacea subtypes, clinical-response percentages and different formulation characteristics. A challenger could argue that the disclosure does not enable the full breadth of those combinations or does not adequately describe all claimed embodiments.

Indefiniteness

The claims use several relative or statistical expressions:

  • “About”
  • “At least about”
  • “Early onset of action”
  • “Primary measure of success”
  • “Secondary measure of success”
  • “Absolute reduction”
  • “At least twice”

Claim 17 presents the most apparent numerical ambiguity because it compares reductions at two time points in a way that may not track ordinary cumulative clinical improvement.

Obviousness

A challenger could combine prior art relating to:

  • Benzoyl peroxide for dermatologic treatment;
  • Topical treatment of rosacea;
  • Microencapsulation or controlled release;
  • Once-daily dosing; and
  • Clinical lesion-count and IGA endpoints.

The patent’s strongest validity defense would likely rely on the particular combination of microencapsulated 5% benzoyl peroxide, rosacea treatment, once-daily dosing and early clinical response.

How strong is the patent estate for Epsolay?

The estate is strongest against close substitutes and weaker against platform alternatives.

Risk category Assessment
Direct 5% microencapsulated benzoyl peroxide cream for rosacea High
Non-encapsulated benzoyl peroxide rosacea product Moderate, depending on claims and labeling
Benzoyl peroxide gel for acne Low under the supplied claims
Combination rosacea product with another active Lower literal risk
Oral rosacea therapy No direct coverage
Topical ivermectin No direct coverage
Topical metronidazole No direct coverage
Azelaic acid products No direct coverage
Biosimilar competition Not applicable
Manufacturing-process substitution Potentially available if the final product avoids claimed formulation and use limitations

The patent’s business value comes from blocking the most direct copy of the approved product, not from controlling the entire rosacea market.

How does Epsolay compare with competing rosacea treatments?

Product or class Active ingredient Typical role Relationship to US 10,945,987
Epsolay 5% benzoyl peroxide Inflammatory rosacea lesions Directly aligned with the patent
Soolantra Ivermectin 1% Papulopustular rosacea Outside the supplied claims
Metrogel and related products Metronidazole Rosacea inflammation Outside the supplied claims
Finacea Azelaic acid 15% Papulopustular rosacea Outside the supplied claims
Oracea Doxycycline Systemic anti-inflammatory treatment Outside the supplied claims
Rhofade Oxymetazoline Persistent facial erythema Outside the supplied claims
Generic benzoyl peroxide acne products Benzoyl peroxide Acne Usually outside the claims unless used in the claimed manner

Epsolay’s differentiation is the combination of a familiar active ingredient with a rosacea indication and encapsulated delivery. The patent attempts to protect the clinical performance associated with that combination.

What generic launch scenarios exist?

Scenario 1: Direct ANDA challenge

A generic applicant develops a 5% benzoyl peroxide cream with comparable microencapsulation and seeks approval for rosacea. This creates the highest infringement risk and the clearest Paragraph IV pathway.

Scenario 2: Non-encapsulated product

A manufacturer develops a non-encapsulated 5% cream. The product may avoid the express encapsulation limitation, but it could face regulatory, safety, tolerability and equivalence challenges.

Scenario 3: Different dosage form

A gel, foam or lotion could avoid the express “cream or emulsion” limitation. The applicant would need to establish whether the dosage form can receive the intended rosacea labeling and whether the clinical profile remains competitive.

Scenario 4: 505(b)(2) product

A sponsor could rely partly on existing benzoyl peroxide data while pursuing a different formulation, strength, delivery system or indication. Patent certification and litigation requirements would still depend on the approved labeling and listed patents.

What licensing deals support the product?

Sol-Gel Technologies developed the encapsulated benzoyl peroxide platform and entered into a commercialization arrangement with Galderma for Epsolay. Galderma’s role gives the product access to an established dermatology commercial infrastructure, while Sol-Gel retains significance as the technology and development company behind the formulation.

The licensing structure increases commercial durability but does not change the legal scope of US 10,945,987. Patent rights remain tied to the issued claims, listed patents, regulatory approvals and any applicable contractual rights.

Key Takeaways

  • US Patent 10,945,987 is a method-of-treatment patent focused on rosacea regimens using encapsulated or microencapsulated benzoyl peroxide.
  • The central commercial embodiment is Epsolay, a once-daily 5% benzoyl peroxide cream approved by FDA in 2022.
  • The independent claims require a cream or emulsion, benzoyl peroxide as the sole active ingredient, a 2.5% to 10% concentration and encapsulated or microencapsulated delivery.
  • Claims 1 and 9 use IGA and inflammatory-lesion response thresholds. Claim 17 uses an unusual early absolute-reduction relationship.
  • The nominal patent expiration is approximately July 30, 2035, subject to patent-term adjustment or extension.
  • The patent does not cover all benzoyl peroxide products, all rosacea treatments or competing active ingredients such as ivermectin, metronidazole, azelaic acid or doxycycline.
  • The principal future challenge would be an ANDA Paragraph IV filing directed to a close copy of the 5% microencapsulated cream.
  • The most credible validity attacks would involve obviousness, enablement, written description and indefiniteness of the clinical and numerical limitations.
  • Biosimilar competition is not relevant because benzoyl peroxide is a small-molecule active.

FAQs

Is US Patent 10,945,987 a composition patent or a method patent?

It is principally a method-of-treatment patent. The claims require administration of a qualifying benzoyl peroxide formulation to a subject with rosacea under specified dosing and clinical-response conditions.

Does the patent cover ordinary 5% benzoyl peroxide acne gel?

Not necessarily. Ordinary acne gel generally lacks the claimed rosacea treatment, cream or emulsion dosage form and encapsulated or microencapsulated delivery.

Can a competitor sell a rosacea product containing another active ingredient?

Potentially. The supplied claims require benzoyl peroxide to be the only active ingredient in the pharmaceutical composition and the sole active ingredient administered during the regimen. A combination product may avoid literal infringement, although other patents or infringement theories could remain relevant.

Why is claim 17 potentially vulnerable?

Claim 17 requires the absolute lesion-count reduction after approximately two weeks to be at least twice the reduction after approximately four weeks. That relationship is technically unusual and may create disputes over how the reductions are measured and whether the claim is definite and supported by the disclosure.

Does Epsolay have biosimilar competition?

No. Biosimilar law applies to biologics. Epsolay contains benzoyl peroxide, a chemical active, so any competing applicant would more likely use an ANDA or 505(b)(2) pathway.

References

  1. Galderma Laboratories, L.P. (2022). Epsolay (benzoyl peroxide) cream, 5%: Prescribing information. U.S. Food and Drug Administration.

  2. Sol-Gel Technologies Ltd. (2021). Methods for treating rosacea. U.S. Patent No. 10,945,987. United States Patent and Trademark Office.

  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

  4. United States Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation resources. USPTO.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,945,987

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mayne Pharma EPSOLAY benzoyl peroxide CREAM;TOPICAL 214510-001 Apr 22, 2022 RX Yes Yes 10,945,987 ⤷  Start Trial TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 18 YEARS OF AGE AND OLDER ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,945,987

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 3130362 ⤷  Start Trial
Canada 3130437 ⤷  Start Trial
Canada 3130439 ⤷  Start Trial
Canada 3130441 ⤷  Start Trial
World Intellectual Property Organization (WIPO) 2020170029 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.